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Introduction
Heparin-induced thrombocytopenia (HIT) is one of the most clinically important drug-induced complications in hospitalized patients. This paradoxical, prothrombotic response to anticoagulant therapy is an immunologic condition in which antibodies to a complex of endogenous platelet factor 4 (PF4) and exogenous heparin activate platelets, leading to aggregation, thrombocytopenia, and, potentially, thromboembolic complications (TECs) [1, 2] . Treatment requires the cessation of heparin and initiation of an alternative anticoagulant, as symptomatic arterial or venous thrombosis associated with a high mortality rate may develop in one-third to one-half of patients with HIT who present with isolated thrombocytopenia [3] [4] [5] .
Seropositivity to PF4/heparin complexes in cardiac surgery patients is common [6] [7] [8] [9] . The actual incidence of HIT in patients undergoing cardiac surgery, however, is reportedly much lower, being typically 0.5-1.8% [10] [11] [12] . Platelet count profiles may be helpful in determining the likelihood of HIT in a patient with thrombocytopenia following cardiopulmonary bypass surgery [13] , but this has not been consistently observed [11] . This complicates the diagnosis of HIT, and potentially exposes patients to hemorrhagic risks if less familiar, non-heparin anticoagulants are used to treat false-positive cases of HIT. However, anti-PF4/ heparin antibodies in the absence of thrombocytopenia may not be entirely benign. For example, elevated antibody levels are associated with myocardial infarction at 30 days in non-thrombocytopenic patients presenting with acute coronary syndromes [14] , arteriovenous fistula thrombosis in non-diabetic hemodialysis patients [15] , and an increased likelihood of death or prolonged hospitalization after cardiac surgery [16] , although direct causality remains unproven. Nevertheless, heparin remains the anticoagulant of choice for > 250 000 cardiac surgeries performed in the USA each year [17] . Up to half of these patients will develop anti-PF4/heparin antibodies, and up to 4500 are projected to develop HIT each year. Although previous studies have suggested an independent thrombotic risk from seropositivity [18] , it remains essential to critically evaluate the relationship between anti-PF4/heparin antibodies and thromboembolism in a population that reflects current clinical and laboratory practice, in a study that is adequately powered to evaluate uncommon thromboembolic events.
The overall aim of our study was to prospectively determine the time-course of anti-PF4/heparin antibody production and its relationship to thromboembolic events, from the day of surgery to 3 months after surgery, and long-term survival. These data will allow us to definitively test the hypothesis that anti-PF4/heparin antibodies are associated with thromboembolism and reduced survival after cardiac surgery.
Materials and methods

Study population
All patients undergoing cardiac surgery requiring cardiopulmonary bypass with heparin anticoagulation were eligible for inclusion in the study. Exclusion criteria included planned postoperative anticoagulant therapy during the hospital stay with warfarin, therapeutic dose low molecular weight heparin, or therapeutic unfractionated heparin. The study was approved by the Institutional Review Board at each participating site, and written informed consent was obtained from all participants.
Study design and measurements
The multicenter, prospective cohort study was conducted through the Rare Thrombotic Diseases Consortium (ClinicalTrials.gov #NCT00237328), and patients were enrolled at five participating centers (Duke University Medical Center, Durham Veterans' Administration Medical Center, Mayo Clinic, the University of Wisconsin, and the University of North Carolina). Lysine analog antifibrinolytic agents were routinely used at all institutions.
Information collected at baseline included patient characteristics (including self-reported race and ethnicity), risk factors for thrombosis (including race), preoperative comorbidities, and operative details. Subsequently, information including all thrombotic events, transfusions, details of hospital readmissions, platelet counts and utilization of antithrombotic medications in the postoperative setting was collected daily during hospitalization, and then at postoperative day 30 and day 90 follow-up time points. These collections were standardized by use of a structured interview format with detailed questionnaires.
Collected data were transferred to an online data entry form by the staff member conducting the interview or test. Unique, de-identified study subject information was transmitted via an encrypted virtual private network to a centralized, password-protected database housed at the Data and Technology Coordinating Center (University of South Florida, Tampa, FL, USA) designed by the Rare Diseases Clinical Research Network. Online forms incorporated checks to minimize transcription and omission errors, including internal validity checks for reasonableness and consistency. Regular assessments of data quality were performed, and automatically generated reminders helped to keep follow-up evaluations within the timeframe. All outcome events were independently reviewed and coded by two independent reviewers to define and assign a date to an event. Strict case definitions were used to minimize reviewer discordance, which was arbitrated by the principal investigator (PI) without knowledge of laboratory or other patient data.
All deaths and alternative anitcoagulant use in this period were independently adjudicated for their potential relationships with complications associated with anti-PF4/ heparin antibodies.
Laboratory samples were collected at baseline, day 5 (pre-discharge), and day 30, processed, and stored at À 80°C until testing was performed centrally at Duke University. The anti-PF4/heparin ELISA was performed with the Enhanced GTI kit, which detects IgG, IgM and IgA anti-PF4/heparin antibodies (GTI, Waukesha, WI, USA); specific IgG isotype assays were not commercially available at the time when the study was open. A 'high-heparin' confirmatory test was performed on all samples with an absorbance OD of > 0.40, as previously described, and a positive result was defined as > 50% inhibition of binding [19] . Data analysis was also performed with an OD cutoff of > 1.0 units, which has been reported to increase the specificity of this assay [20] . Serotonin release assays were performed on samples from patients who were seropositive by both antibody titer and heparin confirmatory step, and reported as previously described [21] .
Outcome measures
The primary, combined endpoint was all-cause death and/or new venous or arterial TECs, including miscellaneous events compatible with HIT, occurring from the time of surgery up to 90 days after surgery. Informed consent included permission to interview next of kin/ healthcare power of attorney, and permission to review the medical record to determine cause of death. Longterm follow-up was obtained from the Duke Death Registry, which uses medical records, and the National Social Security database.
Statistical analysis
A sample size of 800 patients was estimated to be needed to detect a 3% difference in thromboembolic events, assuming a two-fold to 10-fold increased risk attributable to seropositivity and a 25-50% incidence of seropositivity. After the first 400 subjects had completed the protocol, an analysis blinded to antibody status was used to determine outcome rate, and to re-estimate sample size, and confirmed our original estimate of complete follow-up data being required for 800 patients. Assuming an attrition rate of 20%, we targeted enrollment of > 1000 patients.
Demographic data and other characteristics are described as numbers and percentages, and their distribution as mean AE standard deviation or median with interquartile range, as appropriate. The evolution of antibody status with time complicated a 'time to event' analysis; therefore, the chi-square statistic was used to test the relationship between death or TECs and antibody status, as defined by ELISA, OD, heparin confirmatory testing, and the serotonin release assay. The laboratory value (positive/negative) preceding an event (if yes) or that preceding the last follow-up (if no) was related to outcome (yes/no). A P-value of 0.05 was considered to be statistically significant, and no adjustment was made for multiple comparisons. Kaplan-Meier curves were drawn to demonstrate the effect of seropositivity on survival; For patients with evaluable laboratory and demographic data, Cox proportional hazard modeling, adjusted for Euroscore mortality risk, calculated the hazard ratio associated with seropositivity.
Results
A total of 1030 eligible patients were enrolled between August 2006 and May 2009. Eight patients withdrew from the study, and data for one patient were missing. Complete demographic information was available for 990 patients (Table 1) . Missing outcome (n = 18) or laboratory (n = 26) data resulted in a primary analysis dataset of 946 patients, which excluded four patients suffering death or TECs (Fig. 1) . There was little difference in patient demographics according to HIT antibody status, although seronegative patients had a higher incidence of previous arterial thrombosis, hormone replacement therapy, or cardiac catheterization ( Table 1 ). The average age of all patients with complete demographic data was 62 AE 12 years, and 74.6% of participants were male. Overall, 75% of patients underwent coronary artery bypass grafting. The remainder underwent more complex cardiac surgery; there were six reoperations, with four being performed for internal bleeding. In the postoperative period, prophylactic heparin was administered to 39 patients (4.8%) and therapeutic heparin to 41 patients (5.1%).
Outcome measures
Up to 3 months after surgery, there were 17 deaths (1.7%) and 69 TECs affecting a total of 78 patients, as shown in Table 2 . One death was adjudicated as being possibly HIT-related, and the remainder were considered to be unrelated. When the standard, low-titer cutoff (OD > 0.4) was used, eight of 17 patients who died were seropositive and the remaining nine were seronegative. The day 30 anti-heparin/PF4 antibody result in the patient who died with possible HIT was 0.46, and the two patients with confirmed thromboembolism who died were both seronegative prior to their deaths.
Of the 69 thromboembolic events, three (4.3%) occurred before postoperative day 5, classifying them as early complications. Four patients suffered pre-discharge and post-discharge TECs, and two suffered multiple TECs, one of whom died. Although most patients (37/ 69; 53.6%) with a TEC were seropositive, the high prevalence of a positive antibody titer led to no significant association between seropositivity and TECs (Table S1) .
Seven patients were treated with a parenteral, nonheparin anticoagulant in the postoperative setting (four with bivalirudin, two with argatroban, and one with fondaparinux). Subsequent adjudication by study personnel of non-heparin anticoagulant use in these seven patients (Table S2 ) determined that four cases were unrelated, one was unlikely to be related, one was probably related and one was definitely related to HIT. Day 30 ELISA ODs for the latter two patients were 2.19 and 0.62, respectively.
Laboratory testing
Seropositivity, when defined as an OD of > 0.4, was seen in the majority of patients by day 30 (613/946; 65%). The more stringent definitions of OD > 1.0 and OD > 0.4 with > 50% excess heparin confirmatory step, and OD > 1.0 with > 50% excess heparin confirmatory step, generated positive test results in 216 of 946 (23%), 466 of 927 (50%; 2% missing) and 184 of 942 (20%; 0.4% missing), respectively. The evolution of antibody status is illustrated in Fig. 2 , demonstrating how common a positive result is when the definition of OD > 0.4 is used. The relationships between the four definitions of a positive anti-PF4/heparin antibody test result and clinical events are detailed in Table S1 .
Regarding TEC event timing, 26 patients sustained their TEC after day 30, when day 30 results were used as their index laboratory assay, 45 sustained their TEC between days 5 and 30, when day 5 laboratory data were used, and three sustained their TEC before day 5, when their preoperative laboratory data were used to test for an association between anti-heparin/PF4 antibodies and death or TEC. It is of note that 127 patients for who the day 30 results were missing were included in the analysis dataset by evaluating day 5 data as index laboratory tests and the subsequent day 5 to day 30 follow-up period for evaluation of events.
Baseline platelet counts were (287 AE 102) 9 10 9 L -1 with a postoperative nadir of (130 AE 54) 9 10 9 L -1 , representing a 54% decrease. Similar platelet count patterns were seen for seronegative and seropositive patients (Fig. S1 ). Patients experiencing a TEC showed a similar platelet count pattern to the remainder (data not shown).
Chi-square testing with 2 9 2 tables constructed from antibody status positive/negative and clinical event yes/no data showed that 11% of those with an OD of < 0.4 suffered death or TECs, whereas 6% of those with an OD of > 0.4 suffered death or TECs (P = 0.013). In contrast, there were no significant relationships between events (death and/or TECs) and anti-PF4/heparin antibody test status when this was defined as high titer (OD > 1.0) or a heparin confirmatory step was added to a low or high positive titer (Table S1 ). The serotonin release assay was performed on a subset of patients positive by both titer (OD > 0.4) and heparin confirmatory step, and did not differentiate between those who subsequently suffered death and/or a TEC (data not shown).
Long-term outcomes
This pattern persisted during follow-up. Post hoc, longterm follow-up data were available for 669 patients with day 30 antibody titers, with matching Euroscores in 540 patients. The average durations of long-term follow-up were 3.3 years for non-survivors and 6.7 years for survivors. Figure 3 illustrates reduced survival in seronegative patients, with a hazard ratio for death of 1.77 (95% confidence interval [CI] 1.18-2.64) as compared with seropositive patients (OD > 0.4), after adjustment for Euroscore mortality risk (P = 0.0053). This significant association between seronegativity (seropositive if the OD was > 0.4) and reduced survival was only present for this low-titer definition (Table S3) .
Discussion
We prospectively evaluated early and delayed thromboembolic events and long-term survival after cardiac surgery. Seropositivity was defined as either low-titer (OD > 0.4), high-titer (OD > 1.0), heparin-dependent (reduction in antibody/antigen binding following addition of excess heparin), or capable of activating platelets (serotonin release assay reactivity), but the only association that we found was with low-titer seropositive status (OD > 0.4) and a lower incidence of death or thromboembolic events. This unexpected finding may be explained by the confounding effect of a greater incidence of prior arterial thrombosis, actively treated cancer and hormonal therapy usage in the seronegative group, and was not investigated further. Therefore, in the absence of a clinical suspicion of HIT, we reject the hypothesis that early or late thromboembolism is associated with the development of anti-PF4/ heparin antibodies after cardiac surgery. This is currently the largest prospective series designed to relate predefined thromboembolic events to the evolution of the perioperative anti-PF4/heparin antibody response. In keeping with our findings, smaller, prospective series (n > 200 but < 500) have described a similar incidence of preoperative and early postoperative anti-PF4/heparin antibodies [6, 7, 9, 22] that are also unrelated to all-cause thromboembolism. Later in the postoperative period, the 70% seropositivity incidence that we describe after 4 weeks is consistent with the 52% incidence of anti-PF4/heparin antibodies previously measured 6 weeks after surgery reported by Gluckman et al. [9] . They found no relationship between antibodies and the evidence of early saphenous vein graft thrombosis that they observed in one-third of the 368 patients.
Notably, a prospective study by Mattioli et al. reported that anti-PF4/heparin antibodies in the early postoperative period conferred a considerably increased risk of thrombotic events for up to 1 year [18] . However, the rates of thromboembolism and mortality in that series greatly exceeded those that we report, complicating comparison of the two studies. Retrospective series have also shown an increase in thrombotic complications associated with HIT limited to pulmonary embolism [23] or intracardiac thrombosis diagnosed by echocardiography [10] , but anti-PF4/heparin antibodies were only measured if clinically indicated in these studies. In contrast, we systematically tested for anti-PF4/heparin antibodies in all patients regardless of clinical suspicion of HIT.
Antibody status
The definition of a 'positive' anti-PF4/heparin antibody test remains controversial. Antibodies represent a polyclonal response to the complex antigen formed by the binding of the cationic PF4 protein, released from the agranules of activated platelets, and the glycosoaminoglycan moieties of heparin, producing IgA, IgG and IgM isotypes. Most commercially available anti-PF4/heparin antibody ELISA kits detect all three isotypes, whereas antibodies capable of activating platelets are typically of the IgG isotype [24] [25] [26] [27] . Lack of isotype specificity may reduce the overall specificity of a positive test result [27, 28] , although Selleng et al. [22] noted no association between preoperative or postoperative IgG antibodies and thromboembolism, but rather an association between IgM antibodies and non-thrombotic complications after cardiac surgery. Larger studies to confirm this relationship between IgG antibodies and outcomes would still be worthwhile. This possible proinflammatory link seems plausible, as trauma and the accompanying inflammatory response promote anti-PF4/heparin antibody production in the postoperative period [29] . The intense inflammatory Table 1 31 -missing demographic data, none with death or TECs 18 -missing outcome data 26 -no index laboratory data, 4 had TECs
Primary analysis dataset Total 74 deaths or TECs included Total 4 deaths or TECs excluded
Data collected from the day of surgery n = 1021 Fig. 1 . The primary analysis dataset included only patients with evaluable demographic, laboratory and outcome data (n = 946). The index value is the laboratory test preceding an event, or the day 30 blood draw, if no event occurred. Note that if a patient had one or more thromboembolic complications (TECs), this is counted as one event in this figure. stimulus of cardiopulmonary bypass may act as an adjuvant, promoting the formation of non-pathologic antibodies that neither activate platelets nor lead to HIT, but, rather, constitute a non-specific epiphenomenon of a proinflammatory state. The serotonin release assay identifies only platelet-activating antibodies, and is regarded as a gold standard test for pathologically relevant anti-PF4/heparin antibodies [30, 31] . A positive serotonin release assay result is associated with a high likelihood of true HIT, including thrombotic complications, when clinical suspicion of HIT exists, but is typically unavailable to clinicians in a timely manner [32, 33] . However, in asymptomatic patients recovering from cardiac surgery, we found no association between a positive serotonin release assay result and allcause death or thromboembolism.
Thrombocytopenia
Incidence rates of HIT up to 5% have been described after retrospective study [34] , but we observed a lower incidence of HIT, similarly to recent, prospective studies [11, 23, 35] . We did not combine patterns of postoperative thrombocytopenia [36, 37] with anti-PF4/heparin antibody results to diagnose HIT retrospectively; the HIT episodes that we report were diagnosed by the clinical team, as study-related ELISA results were not available at the time of hospitalization. However, we found that platelet counts did not differ between those who did or did not develop either all-cause thromboembolism or anti-PF4/heparin antibodies (Fig. S1 ).
Limitations
One limitation of our study design and analysis was the relatively low incidence of thromboembolism, necessitating caution when our findings are extrapolated to higherrisk cases or those requiring obligatory postoperative anticoagulation. Determination of thromboembolic events relied on clinical diagnoses by the attending physicians, and not on sensitive imaging such as duplex ultrasound or transesophageal echocardiography [10] . Although imaging was only used in this study if clinically indicated, routine imaging may have detected more thrombotic complications, some of which may have only become clinically evident after our 90-day follow-up, or have remained occult. Direct thrombin inhibitor use was infrequent (0.8%) and unlikely to substantially reduce event rates; only one of these patients experienced HIT-related thromboembolism. However, the possibility of type II error resulting from a low event rate does not negate our findings, as gross underpowering of the study is unlikely. Evaluation of > 800 patients approximates the annual caseload of a major cardiac surgery program, but not even a trend towards an association between anti-PF4/ heparin antibodies and thromboembolism was seen.
The pathogenesis of HIT has been extensively studied and well described [5, 38] ; our data do not call into question that anti-PF4/heparin antibodies are the agents of HIT and can lead to thrombosis. However, it seems evident that the anti-PF4/heparin antibodies commonly observed after cardiac surgery are not associated with early or delayed thromboembolism. They do not, therefore, stand alone as a risk factor for thromboembolism, in contrast to associations described after acute coronary syndrome [14] or during dialysis [15] . It is plausible that the almost ubiquitous use of aspirin [39] after cardiac surgery interrupts the pathogenesis of HIT by altering PF4 release, anti-PF4/heparin antibody binding, or platelet activation [40, 41] . Although antiplatelet agents do not universally prevent HIT [42] , their use may explain why anti-PF4/heparin antibodies do not predict graft thrombosis during dialysis [43] or after peripheral vascular HIT, heparin-induced thrombocytopenia; HITT, heparin-induced thrombocytopenia and thrombosis; IVC, inferior vena cava; MI, myocardial infarction; TIA, transient ischemic attack; VTE, venous thromboembolism. During the study period, 17 deaths (A) and 69 thromboembolic events (B) were sustained by 78 patients. Events are segregated into the segments of the study during which they occurred (from enrollment to day 5; from day 5 to day 30; and from day 30 to day 90).
surgery [44] , and are also not associated with thromboembolism after cardiac surgery.
The American College of Chest Physicians Consensus Conference Guidelines (9th edition) recommend that routine testing for anti-PF4/heparin antibodies before cardiac surgery should be avoided, and that a diagnosis of HIT should be considered if the platelet count falls by > 50% between days 5 and 14 following initiation of heparin therapy [30] . Our data confirm that anti-PF4/heparin antibody seropositivity is common in the postoperative period. Because postoperative thrombocytopenia is also common after cardiac surgery, careful clinical evaluation of the platelet profile and the timing of HIT antibody testing is needed to avoid a false-positive diagnosis of HIT [11, 23, 33, 45] .
In conclusion, a positive polyclonal anti-PF4/heparin antibody ELISA result following cardiac surgery is common but does not predict future thromboembolism. Treating a patient with an incidental positive test result is therefore unnecessary in the absence of a clinical diagnosis of HIT, and screening all thrombocytopenic cardiac surgery patients for anti-PF4/heparin antibodies is not warranted. 
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